Core Insights - Compugen Ltd. is a clinical-stage cancer immunotherapy company that specializes in computational target discovery [1][3] - The company will participate in a fireside chat at the Leerink Partners Global Healthcare Conference on March 11, 2025 [1][2] Company Overview - Compugen utilizes its predictive computational discovery platform, Unigen™, to identify new drug targets and biological pathways for cancer immunotherapies [3] - The company has two proprietary product candidates in Phase 1 development: COM701, an anti-PVRIG antibody, and COM902, an antibody targeting TIGIT for solid tumors [3] - Rilvegostomig, a PD-1/TIGIT bispecific antibody, is in Phase 3 development by AstraZeneca under a licensing agreement [3] - GS-0321, a high affinity anti-IL-18 binding protein antibody, is also in Phase 1 development and licensed to Gilead [3] - Compugen's therapeutic pipeline includes early-stage immuno-oncology programs aimed at enhancing anti-cancer immunity [3] - The company is headquartered in Israel with additional offices in San Francisco, CA, and its shares are listed on Nasdaq and the Tel Aviv Stock Exchange under the ticker symbol CGEN [3]

Core Insights - Compugen Ltd. announced a collaboration with Ultima Genomics to enhance its gene sequencing database through the integration of AI/ML powered predictive computational discovery platform, Unigen, and high throughput single cell sequencing technology [1][2] - The collaboration aims to uncover new insights into gene structure for immuno-oncology, with findings presented at the AGBT conference [2][3] - Compugen plans to leverage Ultima's technology to develop proprietary single cell atlases for accelerated discovery of new immunotherapies [2] Group 1: Collaboration and Technology - Compugen's Chief Scientific Officer highlighted the development of algorithms to study gene splicing at single cell resolution, analyzing patient tumor samples to identify potential regulatory mechanisms in immuno-oncology [2] - Ultima Genomics' UG 100 sequencing platform is designed to provide lower cost sequencing and more omics data, facilitating new applications and insights in cancer research [2][6] - The collaboration is expected to transform data-starved applications in immuno-oncology through large-scale data and AI/ML techniques [2] Group 2: Research Findings - A poster presented at the AGBT 2025 meeting detailed the use of 3' single cell sequencing to study patient-derived tumor cells, revealing enhanced potential to study differential splicing at the cell type level [3] - Comparative analysis using tumor samples showed high consistency in single-cell expression levels across Ultima's UG 100 and Illumina's Novaseq 6000 sequencing platforms, with UG 100 providing clearer demarcation of 3' mRNA transcript ends [6] - The gene structure information identified through this approach contributes to the predictive models of Unigen, enhancing the understanding of tumor biology and immune regulation [5][6] Group 3: Company Overview - Compugen is a clinical-stage therapeutic discovery and development company focused on identifying new drug targets and biological pathways for cancer immunotherapies [8] - The company has two proprietary product candidates in Phase 1 development and a bispecific antibody in Phase 3 development through a collaboration with AstraZeneca [8] - Compugen's Unigen platform integrates various biological data, including multi-omics and single-cell RNA sequencing, to discover novel drug targets and understand complex biology [7]

Core Viewpoint - Compugen Ltd. is set to release its fourth quarter and full year 2024 financial results on March 4, 2025, before U.S. markets open, followed by a conference call for a corporate update [1]. Company Overview - Compugen is a clinical-stage cancer immunotherapy company that utilizes its predictive computational discovery platform, Unigen™, to identify new drug targets and biological pathways for cancer treatment [3]. - The company has two proprietary product candidates in Phase 1 development: COM701, an anti-PVRIG antibody, and COM902, an antibody targeting TIGIT for solid tumors [3]. - Rilvegostomig, a PD-1/TIGIT bispecific antibody, is in Phase 3 development by AstraZeneca under a licensing agreement [3]. - GS-0321, a high affinity anti-IL-18 binding protein antibody, is also in Phase 1 development and licensed to Gilead [3]. - Compugen's therapeutic pipeline includes early-stage immuno-oncology programs addressing various immune resistance mechanisms [3]. - The company is headquartered in Israel with offices in San Francisco, CA, and its shares are listed on Nasdaq and the Tel Aviv Stock Exchange under the ticker symbol CGEN [3].

Group 1 - Compugen is an under-the-radar player in the biotech industry, focusing on computationally driven drug discovery [1] - The company targets less-known immune pathways such as PVRIG and IL-18 binding protein, differentiating itself from big pharma's focus on familiar checkpoint inhibitors [1] - Compugen is positioned in a sector poised for exponential expansion, indicating potential for high growth [1]

Core Viewpoint - Compugen Ltd. has initiated a Phase 1 clinical trial for COM503, a potential first-in-class antibody targeting IL-18 binding protein, licensed to Gilead, marking a significant advancement in cancer immunotherapy [1][7]. Group 1: Clinical Trial Details - The Phase 1 trial is a multi-center dose escalation and expansion study aimed at evaluating the safety, tolerability, and pharmacokinetics of COM503 both as a monotherapy and in combination with Gilead's anti-PD1 antibody, zimberelimab, in patients with advanced solid tumors [2][4]. - The trial commenced in the fourth quarter of 2024 as planned, with the primary objectives including assessing safety and identifying the maximum tolerated dose [4]. Group 2: Mechanism of Action - COM503 is designed to block the endogenous IL-18 binding protein, which inhibits the anti-tumor activity of IL-18, thereby potentially enhancing local immune responses against tumors [3][5]. - The unique mechanism of action of COM503 offers a novel treatment option for cancer patients, as noted by clinical researchers involved in the trial [3]. Group 3: Licensing Agreement and Financials - In December 2023, Compugen and Gilead entered into a licensing agreement granting Gilead exclusive rights to develop and commercialize anti-IL-18 binding protein antibodies, including COM503 [5]. - Compugen received an upfront payment of $60 million and an additional $30 million upon IND clearance, with potential future milestone payments totaling up to $758 million, leading to a total deal value of up to $848 million [5]. Group 4: Company Overview - Compugen is a clinical-stage therapeutic discovery and development company utilizing its predictive computational discovery platform, Unigen™, to identify new drug targets for cancer immunotherapies [6][8]. - The company has two other proprietary product candidates in Phase 1 development, COM701 and COM902, targeting different mechanisms in solid tumors [6].

Broad method of use patent protection for COM902, a potential best-in-class reduced Fc, clinical stage, anti-TIGIT antibody, in triple combination with any anti-PD-1 antibody and any anti-PVRIG antibody for the treatment of cancer Further strengthens Compugen's IP portfolio across DNAM-1 axis checkpoint inhibitors HOLON, Israel, Nov. 27, 2024 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN) (TASE: CGEN) a clinicalstage cancer immunotherapy company and a pioneer in computational target discovery, today announced ...

Start Time: 08:30 January 1, 0000 9:30 AM ET Compugen Ltd. (NASDAQ:CGEN) Q3 2024 Earnings Call November 12, 2024, 08:30 AM ET Company Participants Anat Cohen-Dayag - President and CEO David Silberman - CFO Michelle Mahler - Chief Medical Officer Eran Ophir - Chief Scientific Officer Oladapo Yeku - Assistant Professor of Medicine, Harvard Medical School, and Director of Translational Research, Gynecologic Oncology Program Yvonne Naughton - Head of IR and Corporate Communications Conference Call Participants ...

Compugen (CGEN) came out with quarterly earnings of $0.01 per share, missing the Zacks Consensus Estimate of $0.06 per share. This compares to loss of $0.11 per share a year ago. These figures are adjusted for nonrecurring items. This quarterly report represents an earnings surprise of -83.33%. A quarter ago, it was expected that this drug developer would post a loss of $0.08 per share when it actually produced a loss of $0.02, delivering a surprise of 75%. Over the last four quarters, the company has surpa ...

Clinical data presented at SITC 2024 demonstrated COM701 (anti-PVRIG) mediated anti-tumor activity with durable responses and good tolerability profile in tumors typically not responding to immunotherapy, aligned with previous data presented by the Company Plans to initiate, in Q2 2025, an adaptive platform trial in patients with relapsed platinum sensitive ovarian cancer in the maintenance setting, to evaluate single agent COM701 and future combinations representing an unmet need and regulatory and commerc ...

Core Insights - Compugen Ltd. is a clinical-stage cancer immunotherapy company that will participate in a fireside chat at the Stifel 2024 Healthcare Conference on November 18, 2024 [1] - The event will be accessible via a live webcast on the company's Investor Relations website, with a replay available afterward [2] Company Overview - Compugen utilizes its predictive computational discovery platform, UnigenTM, to identify new drug targets and biological pathways for cancer immunotherapies [3] - The company has two proprietary product candidates in Phase 1 development: COM701, an anti-PVRIG antibody, and COM902, an antibody targeting TIGIT for solid tumors [3] - Rilvegostomig, a PD-1/TIGIT bispecific antibody, is in Phase 3 development by AstraZeneca under a licensing agreement [3] - Compugen's pipeline includes early-stage immuno-oncology programs, with COM503, an anti-IL-18 binding protein antibody, having received IND clearance from the FDA and licensed to Gilead [3] - Compugen is headquartered in Israel and has offices in San Francisco, CA, with shares listed on Nasdaq and the Tel Aviv Stock Exchange under the ticker symbol CGEN [3]